Literature DB >> 12640201

Identifying recent HIV infections using the avidity index and an automated enzyme immunoassay.

Barbara Suligoi1, Mario Massi, Claudio Galli, Mauro Sciandra, Fiorella Di Sora, Patrizio Pezzotti, Olga Recchia, Francesco Montella, Alessandro Sinicco, Giovanni Rezza.   

Abstract

We evaluated a procedure for identifying recent HIV infections, using sequential serum samples from 47 HIV-positive persons for whom the seroconversion date could be accurately estimated. Each serum sample was divided into two aliquots: one diluted with phosphate-buffered saline and the other diluted with 1 M guanidine. We assayed the aliquots with the automated AxSYM HIV1/2gO test (Abbott Diagnostics Division), without modifying the manufacturer's protocol. We then calculated the avidity index (AI): the ratio of the sample/cutoff value for the guanidine aliquot to that of the phosphate-buffered saline aliquot. We analyzed 216 serum samples: 34 samples were collected within 6 months of seroconversion (recent seroconversions), and 182 were collected after 6 months. The mean AIs, by time from seroconversion, were 0.68 +/- 0.16 (within 6 months) and 0.98 +/- 0.10 (after 6 months) (P < 0.0001). AI of <0.90 correctly identified 88.2% of recent infections but misclassified as recent infections 13.2% of serum samples collected afterward. The probability of an infection being classified as recent and having AI of > or = 0.90 would be 0.7% in a population with 5% recent infections. AI can identify with a certain degree of accuracy recent HIV infections, and being a quantitative index, it provides different levels of sensitivity and specificity, depending on the selected cutoff value. The standard assay procedure is not modified. This test is simple and inexpensive and could be used for surveillance, decision-making in treatment, and prevention.

Entities:  

Mesh:

Year:  2003        PMID: 12640201     DOI: 10.1097/00126334-200304010-00012

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  39 in total

1.  MSM in Bogotá are living with HIV for extended periods without diagnosis or treatment.

Authors:  Maria Cecilia Zea; Patricia Olaya; Carol A Reisen; Paul J Poppen
Journal:  Int J STD AIDS       Date:  2016-11-21       Impact factor: 1.359

2.  Development and validation of an immunoassay for identification of recent human immunodeficiency virus type 1 infections and its use on dried serum spots.

Authors:  Francis Barin; Laurence Meyer; Rémi Lancar; Christiane Deveau; Myriam Gharib; Anne Laporte; Jean-Claude Desenclos; Dominique Costagliola
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

3.  Development and Evaluation of a Modified Fourth-Generation Human Immunodeficiency Virus Enzyme Immunoassay for Cross-Sectional Incidence Estimation in Clade B Populations.

Authors:  Allison R Kirkpatrick; Eshan U Patel; Connie L Celum; Richard D Moore; Joel N Blankson; Shruti H Mehta; Gregory D Kirk; Joseph B Margolick; Thomas C Quinn; Susan H Eshleman; Oliver Laeyendecker
Journal:  AIDS Res Hum Retroviruses       Date:  2016-05-05       Impact factor: 2.205

4.  Comparison of the avidity index method and the serologic testing algorithm for recent human immunodeficiency virus (HIV) seroconversion, two methods using a single serum sample for identification of recent HIV infections.

Authors:  Elisa Martró; Barbara Suligoi; Victoria González; Vincenzo Bossi; Anna Esteve; Joanne Mei; Vicenç Ausina
Journal:  J Clin Microbiol       Date:  2005-12       Impact factor: 5.948

5.  Decreased specificity of an assay for recent infection in HIV-1-infected patients on highly active antiretroviral treatment: implications for incidence estimates.

Authors:  Antoine Chaillon; Stéphane Le Vu; Sylvie Brunet; Guillaume Gras; Frédéric Bastides; Louis Bernard; Laurence Meyer; Francis Barin
Journal:  Clin Vaccine Immunol       Date:  2012-06-20

Review 6.  The potential role of biomarkers in HIV preventive vaccine trials.

Authors:  Ellen Maclachlan; Kenneth H Mayer; Ruanne Barnabas; Jorge Sanchez; Beryl Koblin; Ann Duerr
Journal:  J Acquir Immune Defic Syndr       Date:  2009-08-15       Impact factor: 3.731

7.  Boosting antibody responses to Plasmodium falciparum merozoite antigens in children with highly seasonal exposure to infection.

Authors:  O J Akpogheneta; S Dunyo; M Pinder; D J Conway
Journal:  Parasite Immunol       Date:  2010-04       Impact factor: 2.280

8.  High percentage of recent HIV infection among HIV-positive individuals newly diagnosed at voluntary counseling and testing sites in Poland.

Authors:  Magdalena Rosińska; Anna Marzec-Bogustawska; Janusz Janiec; Joanna Smoleń-Dzirba; Tomasz Wąsik; Joanna Gniewosz; Małgorzata Zalewska; Gary Murphy; Elaine McKinney; Kholoud Porter
Journal:  AIDS Res Hum Retroviruses       Date:  2013-02-26       Impact factor: 2.205

9.  Comparison of the human immunodeficiency virus (HIV) type 1-specific immunoglobulin G capture enzyme-linked immunosorbent assay and the avidity index method for identification of recent HIV infections.

Authors:  Stephan Loschen; Jörg Bätzing-Feigenbaum; Gabriele Poggensee; Christiane Cordes; Bettina Hintsche; Michael Rausch; Stephan Dupke; Silvia Gohlke-Micknis; Jana Rödig; Osamah Hamouda; Claudia Kücherer
Journal:  J Clin Microbiol       Date:  2007-10-31       Impact factor: 5.948

10.  Sample size methods for estimating HIV incidence from cross-sectional surveys.

Authors:  Jacob Konikoff; Ron Brookmeyer
Journal:  Biometrics       Date:  2015-08-24       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.